A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)

Abstract Background According to current evidence, the best treatment for fit patients with non-resectable pancreatic cancer (PC) is combination chemotherapy, whereas frail patients are recommended gemcitabine (Gem) monotherapy. Randomized controlled trials in colorectal cancer and a post-hoc analys...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Louise Skau Rasmussen, Stine B. Winther, Inna M. Chen, Britta Weber, Lise Ventzel, Gabor Liposits, Julia Sidenius Johansen, Sönke Detlefsen, Ida Egendal, Susy Shim, Signe Christensen, Per Pfeiffer, Morten Ladekarl
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2023-06-01
Serie:	BMC Cancer
Soggetti:	Chemotherapy dose Comorbidity Frail Older patients Pancreatic cancer Randomized study
Accesso online:	https://doi.org/10.1186/s12885-023-11035-6
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!